Glaucoma is chronic, degenerative disorder that damages the eye's optic nerve, may result in vision loss and blindness. Factors such, high prevalence of glaucoma, technological advancement in diagnostic technique, rising treatment awareness are driving the market growth of glaucoma therapeutics globally.

The report titled “Glaucoma Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the overall glaucoma therapeutics market along with the market size and estimates for the duration 2015 to 2025. The research study covers in-depth analysis of market segments based on drug class and different geographical regions.  

In order to help strategic decision makers, the report also includes competitive profiling of the leading players in global glaucoma therapeutics market, attractive investment proposition and market positioning of key manufacturers sections. Other in-depth analysis provided in the report includes:

Geographically, the global glaucoma therapeutics market is studied for the following regional markets:

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East and Africa

Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global glaucoma therapeutics market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global glaucoma therapeutics market. This report concludes with company profiles section that highlights major information about the key players engaged in global glaucoma therapeutics market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global glaucoma therapeutics market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

Based on drug class, the global glaucoma therapeutics market is segmented as follows: 

• Prostaglandins Analogs
• Beta blockers
• Alpha-adrenergic Agonists
• Carbonic Anhydrase Inhibitors
• Combinations Medication

Glaucoma is a chronic, degenerative condition that damages the eye's optic nerve, resulting in vision loss and blindness. Factors such as increase in prevalence of eye disorders, significant unmet medical needs and rise in the incidence of age-related eye disorders are driving the market growth of glaucoma therapeutics globally. It is observed that in the year 2016, prostaglandin analogs was largest revenue generating segment because these are widely prescribed first-line treatments for glaucoma. Different studies indicated that fixed-dose combination such as Dorzolamide and Timolol, Latanoprost and Timolol, Brimonidine and Timolol are widely used in market. Patient adherence is more for fixed-dose combination as they reduces the risk of medication washout and also decrease daily topical preservative load. It is observed that beta blockers is second major revenue generating segment, they may be used alone or combined with other medications. They lower the pressure inside the eye and are generally used to treat open-angle glaucoma. Some adverse effects associated with the use of alpha-adrenergic agonists include increase in heart rate and blood pressure negatively impacting the growth of glaucoma therapeutic market.

For the purpose of this study, the global glaucoma therapeutics market is categorized into:

• North America
• Europe
• Asia Pacific
• Latin America (LATAM)
• Middle East and Africa (MEA)

In the base year 2016, North America dominated the glaucoma therapeutics market in terms of revenue and it is anticipated that it will show steady growth during forecast period of 2016-2024. Factors such as rising geriatric population, upsurge in funding by government agencies and private organizations in healthcare system, increasing incidence of eye disorders, improved diagnostic techniques drive the growth of glaucoma therapeutics market in North America. Europe is the second largest revenue generating regional market for glaucoma therapeutics. U.K., Germany and France are major revenue contributing countries in Europe. It is observed that Middle East and Africa is hold smallest market share and it is anticipated that it will show sluggish market growth during forecast period. Comparatively lower cost of treatment medication hinder the market growth of glaucoma therapeutics in Middle East and Africa. Currently, Asia Pacific is not a major revenue generating segment. However, it is anticipated that it will experience a significant growth during the forecast period. Factors such as increasing population, continuous economic development and developing healthcare infrastructure would contribute the market growth in Asia Pacific during forecast period.